Quelltext anzeigen

Du bist nicht berechtigt, die Seite zu bearbeiten. Grund:

Du kannst den Quelltext dieser Seite betrachten und kopieren:

anchor is [[Collapsing FSGS]] {{tp|p=30624253|t=2019. One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants.|pdf=|usr=}} {{tp|p=31023447|t=2019. The Impact of APOL1 on Chronic Kidney Disease and Hypertension.|pdf=|usr=}} {{tp|p=25168832|t=2014. APOL1 kidney risk alleles: population genetics and disease associations.|pdf=|usr=}} {{tp|p=31601430|t=2020. APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI).|pdf=|usr=}} {{tp|p=30054024|t=2019. Donor's APOL1 Risk Genotype and "Second Hits" Associated With De Novo Collapsing Glomerulopathy in Deceased Donor Kidney Transplant Recipients: A Report of 5 Cases.|pdf=|usr=}} {{tp|p=30343724|t=2018. APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD.|pdf=|usr=}} {{tp|p=22119407|t=2012. Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy.|pdf=|usr=}} {{tp|p=20137840|t=2010. Reappraisal of the impact of race on survival in patients on dialysis.|pdf=|usr=}} {{tp|p=26343748|t=2015. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.|pdf=|usr=}} {{tp|p=22965004|t=2012. Relevance of the ACTN4 gene in African-Americans with non-diabetic end-stage renal disease.|pdf=|usr=}} {{tp|p=30201495|t=2018. Role of Apolipoprotein L1 in Human Parietal Epithelial Cell Transition.|pdf=|usr=}} {{tp|p=30201493|t=2018. APOL1-miR-193 Axis as a Bifunctional Regulator of the Glomerular Parietal Epithelium: Maintaining Parietal Cell Phenotype versus Promoting Podocyte Differentiation.|pdf=|usr=}} {{tp|p=30332315|t=2019. APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function?|pdf=|usr=}} {{tp|p=31241995|t=2019. APOL1 and kidney cell function.|pdf=|usr=}} {{tp|p=29357419|t=2018. Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu.|pdf=|usr=}} {{tp|p=25809272|t=2015. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.|pdf=|usr=}} {{tp|p=21486385|t=2011. The APOL1 gene and allograft survival after kidney transplantation.|pdf=|usr=}} {{tp|p=24504811|t=2014. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.|pdf=|usr=}} {{tp|p=27600725|t=2016. Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: a case report investigation.|pdf=|usr=}} {{tp|p=25281610|t=2015. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status.|pdf=|usr=}} {{tp|p=26668025|t=2016. Association of APOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney Biopsy.|pdf=|usr=}} {{tp|p=24903390|t=2014. Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.|pdf=|usr=}} {{tp|p=22068337|t=2012. Target organ damage in African American hypertension: role of APOL1.|pdf=|usr=}} {{tp|p=29389775|t=2018. Apolipoprotein L1 nephropathies: 2017 in review.|pdf=|usr=}} {{tp|p=21453219|t=2011. Effects of race on albuminuria and risk of cardiovascular and kidney disease.|pdf=|usr=}} {{tp|p=22569246|t=2012. Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.|pdf=|usr=}} {{tp|p=26106375|t=2015. Apolipoprotein L1 (APOL1) Variants (Vs) a possible link between Heroin-associated Nephropathy (HAN) and HIV-associated Nephropathy (HIVAN).|pdf=|usr=}} {{tp|p=30890594|t=2019. Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life.|pdf=|usr=}} {{tp|p=20635188|t=2010. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.|pdf=|usr=}} {{tp|p=27035887|t=2016. Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection.|pdf=|usr=}} {{tp|p=28335839|t=2017. Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans.|pdf=|usr=}} {{tp|p=29180397|t=2018. ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.|pdf=|usr=}} {{tp|p=28696248|t=2017. Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion.|pdf=|usr=}} {{tp|p=27864430|t=2017. APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.|pdf=|usr=}} {{tp|p=27821631|t=2017. APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.|pdf=|usr=}} {{tp|p=27005919|t=2016. Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort.|pdf=|usr=}} {{tp|p=25788523|t=2015. APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.|pdf=|usr=}} {{tp|p=25573910|t=2015. Apolipoprotein L1-associated nephropathy and the future of renal diagnostics.|pdf=|usr=}} {{tp|p=25573908|t=2015. Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.|pdf=|usr=}} {{tp|p=25012173|t=2015. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.|pdf=|usr=}} {{tp|p=26038529|t=2015. APOL1 Risk Alleles Are Associated with Exaggerated Age-Related Changes in Glomerular Number and Volume in African-American Adults: An Autopsy Study.|pdf=|usr=}} {{tp|p=24309185|t=2014. The kidney as a reservoir for HIV-1 after renal transplantation.|pdf=|usr=}} {{tp|p=24722442|t=2014. Explaining the racial difference in AKI incidence.|pdf=|usr=}} {{tp|p=23813212|t=2013. APOL1 and progression of nondiabetic nephropathy.|pdf=|usr=}} {{tp|p=23520206|t=2013. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy.|pdf=|usr=}} {{tp|p=21997397|t=2011. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.|pdf=|usr=}} {{tp|p=21997394|t=2011. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.|pdf=|usr=}} {{tp|p=21997392|t=2011. APOL1 localization in normal kidney and nondiabetic kidney disease.|pdf=|usr=}} {{tp|p=20688934|t=2010. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.|pdf=|usr=}} {{tp|p=30052698|t=2018. APOL1 risk variants and kidney disease: what we know so far.|pdf=|usr=}} {{tp|p=21881214|t=2011. Genetics of kidney failure and the evolving story of APOL1.|pdf=|usr=}} {{tp|p=29971324|t=2018. Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women.|pdf=|usr=}} {{tp|p=31217349|t=2019. Antisense oligonucleotide treatment ameliorates IFN-gamma-induced proteinuria in APOL1-transgenic mice.|pdf=|usr=}} {{tp|p=29903699|t=2018. A Putative Role of Apolipoprotein L1 Polymorphism in Renal Parenchymal Scarring Following Febrile Urinary Tract Infection in Nigerian Under-Five Children: Proposal for a Case-Control Association Study.|pdf=|usr=}} {{tp|p=30466562|t=2018. Expanding the spectrum of APOL1-related renal disease: de novo collapsing glomerulopathy following kidney transplant.|pdf=|usr=}} {{tp|p=30287079|t=2018. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts.|pdf=|usr=}} {{tp|p=25993319|t=2015. Sequencing rare and common APOL1 coding variants to determine kidney disease risk.|pdf=|usr=}} {{tp|p=25853332|t=2015. APOL1 toxin, innate immunity, and kidney injury.|pdf=|usr=}} {{tp|p=25029429|t=2015. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.|pdf=|usr=}} {{tp|p=25635718|t=2015. Immunity unmasks APOL1 in collapsing glomerulopathy.|pdf=|usr=}} {{tp|p=25100047|t=2015. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1.|pdf=|usr=}} {{tp|p=25826538|t=2015. Should kidney donors be genotyped for APOL1 risk alleles?|pdf=|usr=}} {{tp|p=22832513|t=2013. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.|pdf=|usr=}} {{tp|p=24280748|t=2013. JC viruria and kidney disease in APOL1 risk genotype individuals: is this a clue to a gene x environment interaction?|pdf=|usr=}} {{tp|p=23677244|t=2013. JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy.|pdf=|usr=}} {{tp|p=22695330|t=2012. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.|pdf=|usr=}} {{tp|p=31317114|t=2019. APOL1-Associated Kidney Disease in Brazil.|pdf=|usr=}} {{tp|p=31317111|t=2019. Searching for Second Hits for the Development of APOL1-Associated Kidney Disease.|pdf=|usr=}} {{tp|p=28391347|t=2017. Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte.|pdf=|usr=}} {{tp|p=22302261|t=2012. The new era of APOL1-associated glomerulosclerosis.|pdf=|usr=}} {{tp|p=21931123|t=2011. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.|pdf=|usr=}} {{tp|p=27494254|t=2016. A Primate APOL1 Variant That Kills Trypanosoma brucei gambiense.|pdf=|usr=}} {{tp|p=28850570|t=2017. Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients.|pdf=|usr=}} {{tp|p=27138898|t=2016. Knockdown of ApoL1 in Zebrafish Larvae Affects the Glomerular Filtration Barrier and the Expression of Nephrin.|pdf=|usr=}} {{tp|p=24658608|t=2014. MYH9 and APOL1 gene polymorphisms and the risk of CKD in patients with lupus nephritis from an admixture population.|pdf=|usr=}} {{tp|p=26699492|t=2016. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.|pdf=|usr=}} {{tp|p=31838940|t=2020. Variation of ApoL1 Testing Practices for Living Kidney Donors.|pdf=|usr=}} {{tp|p=28494221|t=2017. Does copy number variation of APOL1 gene affect the susceptibility to focal segmental glomerulosclerosis?|pdf=|usr=}} {{tp|p=27599995|t=2016. Impact of APOL1 polymorphism and IL-1beta priming in the entry and persistence of HIV-1 in human podocytes.|pdf=|usr=}} {{tp|p=31664093|t=2019. Nucleosomal dsDNA Stimulates APOL1 Expression in Human Cultured Podocytes by Activating the cGAS/IFI16-STING Signaling Pathway.|pdf=|usr=}} {{tp|p=29110760|t=2017. Apolipoprotein L1 Gene Effects on Kidney Transplantation.|pdf=|usr=}} {{tp|p=29110758|t=2017. APOL1 Renal Risk Variants: Fertile Soil for HIV-Associated Nephropathy.|pdf=|usr=}} {{tp|p=26215860|t=2015. APOL1 Kidney Disease Risk Variants: An Evolving Landscape.|pdf=|usr=}} {{tp|p=24119848|t=2013. APOL1 and nephropathy progression in populations of African ancestry.|pdf=|usr=}} {{tp|p=20347640|t=2010. Genetic basis of nondiabetic end-stage renal disease.|pdf=|usr=}} {{tp|p=28795137|t=2017. Late Reoccurrence of Collapsing FSGS After Transplantation of a Living-Related Kidney Bearing APOL 1 Risk Variants Without Disease Evident in Donor Supports the Second Hit Hypothesis.|pdf=|usr=}} {{tp|p=30371607|t=2019. Mechanisms of Injury in APOL1-associated Kidney Disease.|pdf=|usr=}} {{tp|p=26947522|t=2016. Apolipoprotein L1 and Kidney Disease in African Americans.|pdf=|usr=}} {{tp|p=29886044|t=2018. APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.|pdf=|usr=}} {{tp|p=11863085|t=2002. Focal segmental glomerulosclerosis in African Americans.|pdf=|usr=}} {{tp|p=22952321|t=2012. Collapsing glomerulopathy associated lupus in a black female with homozygous APOL1 mutation.|pdf=|usr=}}

Zurück zur Seite Collapsing FSGS (APOL1).